2025 was a productive year for Amplitude Ventures, with our portfolio and team achieving some important milestones.
Evommune is a great example. In November, the company, which is creating game-changing science to treat chronic inflammatory diseases, IPO’d on the New York Stock Exchange (NYSE: EVMN). following our investment in the company’s Series B and Series C rounds in 2023 and 2024, respectively. This year our portfolio companies raised a combined total of US$226.5 million to advance their programs. In addition, we added more than a dozen talented C-suite and board executives to our portfolio companies, helping them accelerate the clinical and commercial success of those businesses.
Some other major achievements from across the portfolio this year include:
Abdera presented promising Phase 1 clinical data on ABD 147 at the IASLC 2025 World Conference on Lung Cancer.
Congruence Therapeutics named as a “Fierce 15” company. Congruence also received a grant from Michael J. Fox Foundation and successfully raised US$32 million to generate the first clinical proof of concept data with its corrector for MC4R-d driven obesity.
Nomic entered into an agreement with Novo Nordisk to integrate its nELISA™ proteomics platform within Novo’s multi-omics target discovery engine. Nomic also confirmed foundational capability for functional proteomics.
Thryv received FDA IND Clearance for Thryv-1268 and presented data on SGK1 inhibition combined with Jardiance (empagliflozin) at the ESC Congress 2025.
Prilenia entered into a collaboration and license agreement with Ferrer for the commercialization and co-development of Pridopidine and presented PROOF-HD study information at the 2025 Huntington’s Disease (HD) Clinical Research Congress
Plus, Stereo Biotherapeutics and Rime Therapeutics, two companies we co-founded through Pre-Amp, our engine for discovering, incubating, and funding innovation in precision medicine, earned recognition for their pursuit of cutting-edge digital technologies and earned spots in the Merck Digital Sciences Studio.
This year, we hosted the Amplitude Fellowship Class of 2025, which brought eight up-and-coming world-class scientists together to conduct a series of in-depth, one-month explorations to identify hypotheses for novel healthcare ventures. We also hosted numerous exclusive events, including our Annual Symposium, which brought our investors, portfolio CEOs, and leaders in precision medicine together for a day and a half of networking and learning.
Importantly, in 2025, we also grew our team with the addition of Colton Strong, Analyst and Karen Li, Marketing and Communications Manager.
Finally, we would like to extend a special congratulations to our Venture Partner, Nancy Harrison, who was honoured with the 2025 Gold Leaf Award for Industry Leadership (Ecosystem Builder)! Nancy is a pillar of the Canadian life sciences ecosystem and continues guide emerging early-stage life sciences companies through the Investor Readiness Program, a great example of our commitment to company building.
With partnering, financing, and M&A activity on the rise for the biotech sector, we anticipate a busy year ahead with new investments, successful exits, and exciting advancements in precision medicine.
From all of us at Amplitude Ventures and Pre-Amp, we wish you the happiest of holidays and a great 2026!
.png)
